Turkey’s Zer Recognized as “Product Challenger” in Global Procurement Ecosystem
Zer, a Turkey-based company specializing in strategic procurement and sourcing management, has been included – for the first time – on the prestigious Provider Lens™ Quadrant Report of Information Services Group (ISG), a leading global technology research and advisory firm. Updated on a quarterly basis, ISG Provider Lens™ is a practitioner-led service provider comparison, empowered by ISG’s advisory experience and data-driven research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220401005382/en/
For the first time, Turkish procurement services firm Zer has been listed on ISG’s Provider Lens™ Quadrant Report (Photo: Business Wire)
A subsidiary of Turkey's Koç Group, Zer took its place in ISG Provider Lens™ report in both the “Procurement BPO Services” and the “Digital Transformation Services” quadrants for both large accounts and midmarket categories. Zer featured in the same quadrant with the firms who consult to industry giants on Fortune 50.
Zer's brand Promena, which is a strategic procurement software, meanwhile, also made the list (in the “Software Platforms and Solutions” quadrant for large accounts), taking a place alongside globally-recognized service providers.
‘Closely followed by procurement professionals’
According to Zer General Manager Mehmet Apak, ISG’s Provider Lens List is extremely influential in the competitive world of digital solutions. “It is closely followed by supply chain and procurement professionals from all over the world,” Apak says. “Lists like ISG Provider Lens™ serve to raise brand awareness in international markets and enhance Turkey's role in the global procurement ecosystem.”
Underlining that global demand for Promena had recently increased by 50%, Apak went on to assert that “Zer’s inclusion in the ISG Provider Lens™ “is a natural reflection of the qualities we bring to all stakeholders – qualities such as resilience and agility.” Both these qualities are crucial, he adds, “in a business environment that is increasingly unpredictable and in which priorities are constantly changing.”
A ‘Value Leader’ in the global procurement sector
Zer‘s strategic procurement software Promena has also been recognized by SpendMatters, Capgemini, Capterra, Procurement Leaders, Art of Procurement and Sourceforge, all of which follow top digital solutions and procurement brands. Since 2019, Promena was included in SpendMatters’ influential Solutionmap Report. Last year, the same report described the company as a “Value Leader” in the global procurement sector.
“We’re pleased that our company is drawing international attention,” Apak says. “In the digital age, procurement and supply chain management is more essential than ever. It lets businesses connect with the rest of the world, keep costs and risks in check, and overcome the hurdles associated with digital transformation.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005382/en/
Contact information
Tülay Genç
support@b2press.com
+90 (212) 635 70 68
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting26.5.2022 12:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June 9-17; virtual and in Vienna). “We are committed to advancing science that can lead to solutions for patients with serious unmet medical needs, including those with cancer,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “For that reason, we look forward to convening with the oncology community and presenting data from across our portfolio, including both Incyte-led and partnered programs.” Key abstracts accepted by EHA include: Oral Presentation Long-term Efficacy and Safety Results from an Ongoing Open-Label Phase 2 Study of Parsaclisib for the Treatment of Autoimmune Hemolytic Anemia (AIHA) (Abstract #S286. Session: Transfusion and Autoimmune Hemolytic Anemia. Session Time: Friday, June 10, 11:30 a.m. - 12:45 p.m.) Poster Presentations A Real-World Evaluation of the Association
500 Billion Gallons of Water Prevented from Flooding Communities in 2021, Using Xylem Technology26.5.2022 12:00:00 CEST | Press release
Solutions from global water technology company Xylem (NYSE:XYL), helped prevent more than 500 billion gallons of polluted water from flooding communities in 2021, according to its annual Sustainability Report. The report highlights the Company’s work with customers and partners to solve the world’s greatest water challenges. It also details Xylem’s progress to reduce its operational footprint, including cutting Scope 1 and 2 greenhouse gas (GHG) emission intensity by 12 percent and water use by 22 percent, versus 2019. “It’s a great privilege to have a leading portfolio of technologies and services to help our customers and communities solve the water challenges so central to a more sustainable world,” said Patrick Decker, president and CEO of Xylem. “We have a responsibility to make a difference, working alongside our customers and partners, and the communities we all serve. That’s why our sustainability report is more than a set of numbers. It’s a report card on the difference we’re
H.I.G. Capital Expands Its Capital Formation Middle East Team with the Addition of Oliver Slade26.5.2022 12:00:00 CEST | Press release
H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with over $49 billion of capital under management, is pleased to announce that Oliver Slade has joined the firm’s Capital Formation Group, as a Managing Director, based in Dubai. Oliver will be responsible for capital raising and investor relations activities in the Middle East. He has been based in the region since 2008 and has over 17 years of experience in alternative assets. Oliver joins H.I.G. from Partners Group, where he was the Head of Middle East and Africa, responsible for the development and capital raising activities across private markets funds and solutions in the region. Prior to Partners Group, Oliver held a similar role at GAM investments. Jordan Peer Griffin, Executive Managing Director and Global Head of Capital Formation, commented: “We are delighted to welcome Oliver to H.I.G. Given his experiences in the region, Oliver is a key addition to establish a local presence in the Middle East, wh
SCREEN Increases Efforts to Reduce the Environmental Impact of the Semiconductor Industry26.5.2022 10:43:00 CEST | Press release
SCREEN Semiconductor Solutions Co., Ltd. (SCREEN SPE), a subsidiary of SCREEN Holdings Co., Ltd., has announced it will increase its efforts to reduce the company’s environmental overall impact. The SCREEN Group is committed to both achieving a sustainable global society and to improving its sustainable value (social value) and has formulated a medium-term management plan titled Sustainable Value 2023 targeting these goals. The plan identifies specific issues in each of the environmental, social, and governance (ESG) fields. Concerning the environment, SCREEN is working to provide products and services that actively contribute to the reduction of ecological burden. Its efforts include improving the environmental performance of its products, reducing the effects of its business activities on climate change, promoting effective utilization of water resources, increasing recycling of products and parts, and helping to preserve biodiversity. Concretely, SCREEN SPE seeks to reduce the impac
CARVYKTI ® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:10:00 CEST | Press release
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel in December 2017. CARVYKTI® is a chimeric antigen receptor T-cell (CAR-T) therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies.1 CAR-T therapy is specifically developed